PAH and phenylketonuria: Cofactor therapy using sapropterin (a synthetic BH4 analog) aids in reducing phenylalanine levels by activating residual PAH enzyme activity but is only effective in a subset of patients with BH4-responsive form of PKU​ with BH4 deficiency.